Baird analyst Robert Mason lowered the firm’s price target on Novanta (NOVT) to $160 from $169 and keeps a Neutral rating on the shares. The firm The firm updated its model following its mixed Q4 report. New products are driving the 2025 outlook which with upside possible if markets rebound.
Education
About Us
Working with TipRanks
Follow Us
1